Editas Medicine, Inc. · NASDAQ:EDIT
Editas Medicine — Investor Presentation (June 2026)
17 slides from Editas Medicine's investor presentation, June 2026
Slide 1: Driving Durable, Transformative Medicines Forward
Driving Durable, Transformative Medicines Forward June 2026 1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements and information within the meaning of The Private Securities Litigation Re form Act of 1995. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘pot
Slide 3: EDIT-401: Potential to Transform the Hyperlipidemia Treatment Landscape
Transformative Address significant unmet needs via Therapeutic one-time, durable treatment with meaningful patient and broader healthcare system impact Potential Novel Differentiated strategy unlocked by Therapeutic functionally upregulating protein expression Mechanisms Delivery platform enables pr
Slide 4: Editas' Differentiated In Vivo Gene Editing Strategy
Editas’ Differentiated In Vivo Gene Editing Strategy Genetic Genetic Non-genetic Knockdown Correction Knockdown* Functional Upregulation Edits Non-Coding Regions Addresses All Patients** One-time, Curative Potential Differentiated Therapeutic Strategy Harnessing the power of CRISPR gene editing and
Slide 5: Transformative LDL-C Lowering Potential
EDIT-401: Transformative LDL-C Lowering Potential Average LDL-C Reduction with Current Treatments EDIT-401 Uniquely vs. EDIT-401 Potential Positioned Time Baseline Intensive, lifelong reduction of LDL-C provides maximal clinical benefit7 Statins % Reduction Current standard of care May eliminate mul
Slide 6: EDIT-401: Potential to Transform the Treatment of Hyperlipidemia
EDIT-401: Potential to Transform the Treatment of Hyperlipidemia Delivering Addressing Aligning Best-in-Class Significant At-Risk Patient Benefits with Therapy Populations System Costs Single dose of EDIT-401 One-time treatment has achieved ~90% or ~10 million U.S. patients potential to enable great
Slide 7: Large Opportunity Across At-risk Hyperlipidemia Patient Populations
EDIT-401: Large Opportunity Across At-risk Hyperlipidemia Patient Populations 70 million US patients Heterozygous Familial Hypercholesterolemia with hyperlipidemia1 Highly prevalent monogenic genetic disorder that leads to elevated LDL-C2 1.2 Million ~10–20x 97% people are affected increased risk of
Slide 8: Potential to Address Significant Burden on Healthcare Systems
EDIT-401: Potential to Address Significant Burden on Healthcare Systems Limited Benefit ~75% of ASCVD patients do not achieve LDL-C goals1,2 EDIT-401 is poised to transform the treatment landscape and Inconvenient Regimens align clinical economic value Current Multi-drug approach with Standard of ch
Slide 9: Potential Best-in-class LDL-C Reduction
EDIT-401: Potential Best-in-class LDL-C Reduction EDIT-401 Therapeutic Strategy for LDLR upregulation • Edits non-coding, regulatory regions • ~10-40% functional editing achieves >90% mean LDL-C reduction in preclinical studies1 • At least 6-fold mean LDLR protein increase in preclinical studies 1 •
Slide 10: Therapeutic Strategy De-Risked by Human Genetics
EDIT-401: Therapeutic Strategy De-Risked by Human Genetics 7 Icelandic family members identified as carriers of partial LDLR 3’ UTR deletion1 Plasma LDL-C levels1 ∆ICE 3’ UTR carriers deletion carriers n = 101,857 Icelandic non-carriers Mean plasma LDL-C (mmol/l) No Adverse Events Observed in Icelan
Slide 11: Achieved ~90% or Greater Mean Reduction in LDL-C and Lp(a) in NHPs
EDIT-401: Achieved ~90% or Greater Mean Reduction in LDL-C and Lp(a) in NHPs A single dose of EDIT-401 LDL-C reductions Reductions in LDL-C and Promising preclinical achieved ~90% or remained durable Lp(a) were highly safety profile with no greater mean reduction through ~6 correlated, highlighting
Slide 12: Durable, Rapid, and Robust LDL-C Reduction in NHPs
EDIT-401: Durable, Rapid, and Robust LDL-C Reduction in NHPs Single dose of EDIT-4011 40 Vehicle (n=4) 1.5 mg/kg (n=4) 2.0 mg/kg (n=4) 3.0 mg/kg (n=4) • Rapid and robust LDL-C reduction 30 across a dose range 20 (% change from baseline) 10 0 -10 -20 • At least 6-fold mean increase in LDL-C -30 -40 L
Slide 13: Achieved >90% Mean LDL-C Reduction in Wildtype Mice with LDLR Loss-of-Function
EDIT-401: Achieved >90% Mean LDL-C Reduction in Wildtype Mice with LDLR Loss-of-Function and High LDL-C Wildtype Mice and Mice Heterozygous for LDLR Loss-of- Function with High Baseline LDL-C1 500 WT Vehicle WT Edited ✓ >90% mean LDL-C 400 Ldlr+/- Vehicle reduction Ldlr+/- Edited LDL-C mg/dL 300 ✓ S
Slide 14: Up To ~90% Mean Lp(a) Reduction Achieved in NHPs
EDIT-401: Up To ~90% Mean Lp(a) Reduction Achieved in NHPs Elevated Lp(a) adds independent genetically driven risk that can persist even when LDL-C is at goal Single dose of EDIT-4011 • Dose-dependent Lp(a) reduction Vehicle 1.5 mg/kg 3 mg/kg 6 mg/kg (n=3) (n=3) (n=3) (n=3) 60 50 40 • Rapid Lp(a) re
Slide 15: Preclinical Safety Profile
EDIT-401: Preclinical Safety Profile Single dose of EDIT-401 EDIT-401 safety observations at therapeutically relevant dose1: Group Mean ALT Group Mean Bilirubin 1.0 600 • Well-tolerated with no 500 Vehicle (n=9) 0.8 Vehicle (n=9) 1.5 mg/kg (n=14) adverse clinical 1.5 mg/kg (n=14) observations 400 0.
Slide 16: EDIT-401: Key Anticipated Milestones
Driving Durable, Transformative Medicines Forward EDIT-401: Key Anticipated Milestones Delivering Best- in-Class Therapy 2026 2027 Present additional preclinical data for EDIT-401 Complete enrollment in by mid-2026 clinical trial, dose-finding portion Addressing Submit CTN for EDIT-401 by mid-2026
Slide 17: Programs Positioned for Development
Programs Positioned for Development PROGRAM (OR DISEASE CANDIDATE) PRECLINICAL IND/CTA EARLY-STAGE LATE-STAGE DEVELOPMENT ENABLING CLINICAL CLINICAL & COMMERCIAL PARTNER CARDIO VASCUL AR EDIT-401: Hyperlipidemia H EM OG L OB I N - O PA TH I E S In Vivo HSC Editing – sickle cell disease In vivo HSC E